German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback